Gastroenteropancreatic endocrine tumors: Clinical characterization before therapy

Nature Clinical Practice Endocrinology and Metabolism

Volumn 3, Issue 3, 2007, Pages 228-239

  Baudin, Eric ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Carcinoid tumor; Endocrine tumor; Islet cell carcinoma; Neuroendocrine tumor; Pancreatic endocrine tumor

Indexed keywords

BIOLOGICAL MARKER; SOMATOSTATIN; SOMATOSTATIN RECEPTOR;

CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CANCER THERAPY; COMORBIDITY; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; EMBRYOLOGY; ENDOCRINE TUMOR; GASTROENTEROPANCREATIC ENDOCRINE TUMOR; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN VARIANT; REVIEW; RISK FACTOR; VASCULARIZATION;

ENDOCRINE GLAND NEOPLASMS; GASTROINTESTINAL NEOPLASMS; HUMANS; MODELS, BIOLOGICAL; PANCREATIC NEOPLASMS; PROGNOSIS; RECEPTORS, SOMATOSTATIN; RISK FACTORS;

EID: 33847195798     PISSN: 17458366     EISSN: 17458374     Source Type: Journal    
DOI: 10.1038/ncpendmet0425     Document Type: Review

References (81)

1. Plöckinger U et al. (2004) Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. Neuroendocrinology 80: 394-424
2. Modlin IM et al. (2003) A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97: 934-959
3. Quaedvlieg PFHJ et al. (2001) Epidemiology and survival in patients with carcinoid disease in the Netherlands: an epidemiological study with 2391 patients. Ann Oncol 12: 1295-1300
4. Hemminki K and Li X (2001) Familial carcinoid tumors and subsequent cancers: a nation-wide epidemiologic study from Sweden. Int J Cancer 94: 444-448
5. Skuladottir H et al. (2002) Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-bases study in Denmark. Lung Cancer 37: 127-135
6. Hamilton SR and Aaltonen LA (2000) World Health Organisation Classification of Tumors. Pathology and Genetics of Tumours of the Digestive System. Lyon: IARC Press
7. Travis WD et al. (2004) World Health Organisation Classification of Tumors. Pathology and Genetics of the Lung, Pleura, Thymus and Heart. Lyon: IARC Press
8. DeLellis RE et al. (2004) World Health Organisation Classification of Tumors. Pathology and Genetics of Tumours of Endocrine Organs. Lyon: IARC Press
9. Sturm N et al. (2003) Thyroid transcription factor 1 and cytokeratins 1, 5, 10, 14 (34βE12) expression in basaloid and large-cell neuroendocrine carcinomas of the lung. Hum Pathol 32: 918-925
10. Williams ED and Sandler M (1963) The classification of carcinoid tumours. Lancet 1: 238-239
11. Soga J (2003) Carcinoid and their variant endocrinomas. An analysis of 11,842 reported cases. J Exp Clin Cancer Res 22: 517-530
12. Travis WD et al. (1998) Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 22: 934-944
13. Moran CA and Suster S (2000) Neuroendocrine carcinomas (carcinoid tumor) of the thymus. A clinicopathological analysis of 80 cases. Am J Clin Pathol 114: 100-110
14. Mitry E et al. (1999) Treatment of poorly-differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 81: 1351-1355
15. Garcia-Yuste M et al. (2000) Prognostic factors in neuroendocrine lung tumors: a Spanish multicenter study. Ann Thorac Surg 70: 258-263
16. Takei H et al. (2002) Large cell neuroendocrine carcinoma of the lung: a clinicopathologic study of eighty-seven cases. J Thorac Cardiovasc Surg 124: 285-292
17. Cardillo G et al. (2004) Bronchial carcinoid tumors: nodal status and long-term survival after resection. Ann Thorac Surg 77: 1781-1785
18. Soga J (2005) Early-stage carcinoids of the gastrointestinal tract. Cancer 103: 1587-1595
19. Lowney JK et al. (1999) Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: correlation with primary size. Surgery 125: 1043-1049
20. Onaitis MW et al. (2000) Gastrointestinal carcinoids: characterization by site of origin and hormone production. Ann Surg 232: 549-556
21. Shebani KO et al. (1999) Prognosis and survival in patients with gastrointestinal tract carcinoid tumors. Ann Surg 29: 815-823
22. Rindi G et al. (1999) ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 116: 532-542
23. Borch K et al. (2005) Gastric carcinoids. Biologic behavior and prognosis after differentiated treatment in relation to type. Ann Surg 242: 64-73
24. Gullo L et al. (2003) Nonfunctioning pancreatic endocrine tumors: a multicenter clinical study. Am J Gastroenterol 98: 2435-2439
25. Hoffmann KM et al. (2005) Duodenal neuroendocrine tumors: classification, functional syndromes, diagnosis and medical treatment. Best Pract Res Clin Gastroenterol 19: 675-697
26. Baudin E et al. (1999) Screening for multiple endocrine neoplasia type 1 and hormonal production in apparently sporadic neuroendocrine tumors. J Clin Endocrinol Metab 84: 69-75
27. 111I-diethylene triaminepentaacetate-D-Phepentetreotide scintigraphy in the localization of ectopic adrenocorticotropin-secreting tumors causing Cushing's syndrome. J Clin Endocrinol Metab 89: 2214-2221
28. Leboulleux S et al. (1999) Gastroenteropancreatic neuroendocrine tumor metastases to the thyroid gland: differential diagnosis with medullary thyroid carcinoma. Eur J Endocrinol 140: 187-191
29. Janson ET et al. (1997) Carcinoid tumors: analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 8: 685-690
30. Baudin E et al. (1998) Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer 78: 1102-1107
31. Bajetta E et al. (1999) Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Br J Cancer 86: 858-865
32. Nehar D et al. (2004) Interest of chromogranin A for diagnosis and follow-up of endocrine tumours. Clin Endocrinol (Oxf) 60: 644-652
33. Goebel S et al. (1999) Prospective study of the value of serum chromogranin A or serum gastrin levels in the assessment of the presence, extent, or growth of gastrinomas. Cancer 85: 1470-1483
34. Baudin E et al. (2001) Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. Ann Oncol 12: S79-S82
35. Stridsberg M et al. (2003) A comparison between three commercials kits for chromogranin A measurements. J Endocrinol 177: 337-341
36. Eriksson B et al. (1989) Neuroendorine pancreatic tumors. Clinical findings in a prospective study of 84 patients. Acta Oncol 28: 373-377
37. Meijer WG et al. (2000) Discriminating capacity of indole markers in the diagnosis of carcinoid tumors. Clin Chem 46: 1588-1596
38. Panzuto F et al. (2004) Utility of combined use of plasma levels of chromogranin A and pancreatic polypeptide in the diagnosis of gastrointestinal and pancreatic endocrine tumors. J Endocrinol Invest 27: 6-11
39. Reubi JC et al. (1990) Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 50: 5969-5977
40. Adams S et al. (1998) Metabolic (PET) and receptor (SPET) imaging of well- and less well-differentiated tumours: comparison with the expression of the Ki-67 antigen. Nucl Med Commun 19: 641-647
41. Reubi JC and Waser B (2003) Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor imaging. Eur J Nucl Med Imaging 30: 781-793
42. Janson ET et al. (1996) A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. Cancer Res 56: 2561-2565
43. 111In-DTPA-D-PheI] octreotide in somatostatin receptor positive organs. J Nucl Med 44: 1315-1321
44. Ricke J et al. (2001) Standardisation of imaging in neuroendocrine tumors: results of a European delphi process. Eur J Radiol 37: 8-17
45. Brandi ML et al. (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86: 5658-5671
46. Cadiot G et al. (1996) Preoperative detection of duodenal gastrinomas and peripancreatic lymph nodes by somatostatin receptor scintigraphy. Gastroenterology 111: 845-854
47. Langer P et al. (2004) Prospective evaluation of imaging procedures for the detection of pancreaticoduodenal endocrine tumors in patients with multiples endocrine neoplasia type 1. World J Surg 28: 1317-1322
48. Ichikawa T et al. (2000) Islet cell tumor of the pancreas: biphasic CT versus MR imaging in tumor detection. Radiology 216: 163-171
49. Thoeni RF et al. (2000) Detection of small, functional islet cell tumors in the pancreas: selection of MR imaging sequences for optimal sensitivity. Radiology 214: 483-490
50. Horton KM et al. (2004) Carcinoid tumors of the small bowel: a multitechnique imaging. AJR Am J Roentgenol 182: 559-567
51. Dromain C et al. (2003) MR imaging of hepatic metastases caused by neuroendocrine tumors: comparing four techniques. AJR Am J Roentgenol 180: 121-128
52. Dromain C et al. (2005) Detection of liver metastases from endocrine tumors: a prospective comparison of somatostatin receptor scintigraphy, computed tomography, and magnetic resonance imaging. J Clin Oncol 23: 70-78
53. 123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20: 716-731
54. Alexander HR et al. (1998) Prospective study of somatostatin receptor scintigraphy and its effect on operative outcome in patients with Zollinger-Ellison syndrome. Ann Surg 228: 228-238
55. Gotthardt M et al. (2003) Influence of somatostatin receptor scintigraphy and CT/MRI on the clinical management of patients with gastrointestinal neuroendocrine tumors: an analysis in 188 patients. Digestion 68: 80-85
56. Musi M et al. (1998) Bronchial carcinoid tumours: a study on clinicopathological features and role of octreotide scintigraphy. Lung Cancer 22: 97-102
57. Gibril F et al. (1998) Bone metastases in patients with gastrinomas: a prospective study of bone scanning, somatostatin receptor scanning, and magnetic resonance image in their detection, frequency, location, and effect of their detection on management. J Clin Oncol 16: 1040-1053
58. 177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 23: 2754-2762
59. Oberg K and Eriksson B (2005) Nuclear medicine in the detection, staging and treatment of gastrointestinal carcinoid tumours. Best Pract Res Clin Endocrinol Metab 19: 265-276
60. Calender A (2000) Molecular genetics of neuroendocrine tumors. Digestion 62 (Suppl 1): 3-18
61. Triponez F et al. (2006) Epidemiology data on 108 MEN 1 patients from the GTE with isolated nonfunctioning tumors of the pancreas. Ann Surg 243: 265-272
62. Bassett JHD et al. (1998) Characterization of mutations in patients with multiple endocrine neoplasia type 1. Am J Hum Genet 62: 232-244
63. Giraud S et al. (1998) Germ-line mutation analysis in patients with multiple endocrine neoplasia type 1 and related disorders. Am J Hum Genet 63: 455-467
64. Ellard S et al. (2005) Detection of an MEN1 gene mutation depends on clinical features and supports current referral criteria for diagnostic molecular genetic testing. Clin Endocrinol (Oxf) 62: 169-175
65. Hammel P et al. (2000) Pancreatic involvement in von Hippel-Lindau disease. Gastroenterology 119: 1087-1095
66. Grandberg et al. (1999) Plasma chromogranin A in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab 84: 2712-2717
67. Habal N et al. (2000) Gastrointestinal carcinoid tumors and second primary malignancies. J Surg Oncol 75: 310-316
68. Lim E et al. (2005) The impact of stage and cell type on the prognosis of pulmonary neuroendocrine tumors. J Thorax Cardiovasc Surg 130: 969-972
69. Madeira I et al. (1998) Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 43: 422-427
70. Moertel CG (1987) An odyssey in the land of small tumors. J Clin Oncol 10: 1503-1522
71. Weber HC et al. (1995) Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: a prospective long-term study. Gastroenterology 108: 1637-1649
72. Granberg D et al. (2000) Prognostic markers in patients with typical bronchial carcinoid tumors. J Clin Endocrinol Metab 85: 3425-3430
73. Beasley MB et al. (2000) Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol 31: 1255-1265
74. McDermott EWM et al. (1994) Prognostic variables in patients with gastrointestinal carcinoid tumours. Br J Surg 81: 1007-1009
75. Greenberg RS et al. (1987) Prognostic factors for gastrointestinal and bronchopulmonary carcinoid tumors. Cancer 60: 2476-2483
76. Soreide JA et al. (2000) Gastrointestinal carcinoid tumors: long-term prognosis for surgically treated patients. World J Surg 24: 1431-1436
77. Pelosi G et al. (1996) Endocrine tumors of the pancreas: Ki-67 immunoreactivity on paraffin sections in an independent predictor for malignancy. Hum Pathol 27: 1124-1134
78. Hochwald SN et al. (2002) Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low grade and intermediate-grade groups. J Clin Oncol 20: 2633-2642
79. Yu F et al. (1999) Prospective study of the clinical course, prognostic factors, cause of death, and survival in patients with long-standing Zollinger-Ellison syndrome. J Clin Oncol 17: 615-630
80. Chaudhry A et al. (1992) A study of biological behavior based on the expression of a proliferating antigen in neuroendocrine tumors of the digestive system. Tumour Biol 13: 27-35
81. Moller JE et al. (2003) Factors associated with progression of carcinoid heart disease. N Engl J Med 348: 1005-1015